Cited by Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia

Repeated Omicron exposures redirect SARS-CoV-2–specific memory B cell evolution toward the latest variants DOI

Ryutaro Kotaki, Saya Moriyama,

Shintaro Oishi

et al.

Science Translational Medicine, Journal Year: 2024, Volume and Issue: 16(761)

Published: Aug. 21, 2024

Immunological imprinting by ancestral SARS-CoV-2 strains is thought to impede the robust induction of Omicron-specific humoral responses Omicron-based booster vaccines. Here, we analyzed specificity and neutralization activity memory B (B mem ) cells after repeated BA.5 exposure in individuals previously imprinted strain–based mRNA After a second exposure, with spike protein–skewed reactivity were promptly elicited, correlating preexisting antibody titers. Clonal lineage analysis identified BA.5-skewed that had redirected their from strain through somatic hypermutations. Moreover, exhibited accelerated development compared de novo derived naïve repertoires. This demonstrated greater resilience viral point mutation adaptation recent Omicron variants HK.3 JN.1, months suggesting existing elicited older vaccines can redirect toward newly evolving variants.

Language: Английский

Citations

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era DOI

Shanti Pather, Alexander Muik, Ruben Rizzi

et al.

Expert Review of Vaccines, Journal Year: 2023, Volume and Issue: 22(1), P. 650 - 661

Published: July 7, 2023

Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein. In response to the emergence sub-lineages, variant-adapted that contain encode for protein components have been developed.Areas covered This review presents currently available clinical immunogenicity safety data on versions BNT162b2 messenger RNA (mRNA) vaccine summarizes expected mechanism action, rationale development, these vaccines. addition, challenges encountered during development regulatory approval are discussed.Expert opinion Omicron-adapted provide a wider breadth potentially more durable protection against antigenically aligned variants when compared with original vaccine. As SARS-CoV-2 continues evolve, further updates may be required. To facilitate this, globally harmonized process transition updated is needed. Next-generation approaches broader future variants.

Language: Английский

Citations

A Meta-Analysis on the Immunogenicity of Prototype, Monovalent-adapted and Bivalent vaccines against SARS-CoV-2 Wildtype, Omicron BA.1 and Omicron BA.4/5 in Healthy Adults. DOI

Jo‐Lewis Banga Ndzouboukou, Abdul A. Kamara, Nadeem Ullah

et al.

Virology, Journal Year: 2025, Volume and Issue: 606, P. 110509 - 110509

Published: March 20, 2025

Language: Английский

Citations

The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report DOI

Ssu-Yu Chen, Chien‐Yu Lin, Hsin Chi

et al.

Life, Journal Year: 2023, Volume and Issue: 13(10), P. 2094 - 2094

Published: Oct. 21, 2023

Vaccination has been a game-changer in the long battle against COVID-19. However, waning vaccine-induced immunity and immune evasion of emerging variants create challenges. The rapid-fire development bivalent vaccines (BVs), comprising ancestral strains new variant, was authorized to prevent COVID-19, but effectiveness updated remains largely unclear. Electronic databases were searched investigate immunogenicity reactogenicity BVs humans. As March 2023, 20 trials identified. Compared with monovalent vaccination, induced similar. demonstrated approximately 33-50% higher values additional variant strains. An observational cohort study showed clinical BVs. adverse events In conclusion, our systematic review found that had equal without safety concerns. Approximately increased antibody titers observed subjects BV vaccine moderate heterogeneity, especially for BA.1-containing

Language: Английский

Citations

tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains DOI

Daniel Ivanusic, Josef Maier,

Suheda Icli

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(3), P. 109123 - 109123

Published: Feb. 5, 2024

Conventional neutralizing enzyme-linked immunosorbent assay (ELISA) systems for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mimic the protein-protein interaction between angiotensin-converting enzyme (ACE2) and receptor-binding domain (RBD). However, an easy rapidly adaptative ELISA-based system testing antibodies against upcoming SARS-CoV-2 variants is urgently needed. In this study, we closed gap by developing a tANCHOR-cell-based RBD neutralization that avoids time-consuming protein expression purification followed coating on ELISA plates. This cell-based can be adopted to monitor (NAbs) variants. We show results obtained with strongly correlate commercially available surrogate assays NAbs. Moreover, technique directly measure binding cell-surface-exposed RBDs soluble ACE2. With technique, degree of antibody escape elicited emerging in current vaccination regimens determined reliably.

Language: Английский

Citations

Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom DOI

Cale Harrison,

Rebecca Butfield, Benjamin Yarnoff

et al.

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 730 - 739

Published: July 29, 2024

Background Updating vaccines is essential for combatting emerging coronavirus disease 2019 (COVID-19) variants. This study assessed the public health and economic impact of a booster dose an adapted vaccine in United Kingdom (UK).

Language: Английский

Citations

Modeling the potential public health impact of different vaccination strategies with an adapted vaccine in South Africa DOI

Nadine Al Akoury,

Júlia Spinardi,

Hammam Haridy

et al.

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 750 - 760

Published: Aug. 23, 2024

COVID-19 vaccines adapted to newly emerging circulating variants are necessary better protect the population due evolving nature of SARS-CoV-2 virus.

Language: Английский

Citations

Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2 DOI

Anna Vakhrusheva, Ekaterina A. Romanovskaya-Romanko, Marina Stukova

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(10), P. 1200 - 1200

Published: Oct. 21, 2024

SARS-CoV-2, the causal agent of COVID-19 pandemic, is characterized by rapid evolution, which poses a significant public health challenge. Effective vaccines that provide robust protection, elicit strong immune responses, exhibit favorable safety profiles, and enable cost-effective large-scale production are crucial. The RBD-Fc-based Betuvax-CoV-2 vaccine has previously demonstrated profile induced anti-SARS-CoV-2 humoral response in clinical trials. Due to evolution emergence new SARS-CoV-2 strains, relevance bivalent formulations increased.

Language: Английский

Citations

Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia DOI

Nadine Al Akoury,

Júlia Spinardi,

Hammam Haridy

et al.

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 6, 2024

Background The dynamic evolution of the virus causing COVID-19 necessitates development adapted vaccines to protect against emerging variants.

Language: Английский

Citations